4//SEC Filing
Xenon Pharmaceuticals Inc. 4
Accession 0001209191-14-068343
$XENECIK 0001582313operating
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 8:33 PM ET
Size
12.1 KB
Accession
0001209191-14-068343
Insider Transaction Report
Form 4
STEIN EVAN A.
Director
Transactions
- Conversion
Common Shares
2014-11-09+1,038,964→ 1,038,964 total(indirect: By Lipoterx, Ltd.) - Conversion
Common Shares
2014-11-09+967→ 967 total(indirect: By LLC) - Conversion
Series B Preferred Shares
2014-11-09−967→ 0 total(indirect: By LLC)→ Common Shares (967 underlying) - Conversion
Series E Preferred Shares
2014-11-09−1,038,964→ 0 total(indirect: By Lipoterx, Ltd.)→ Common Shares (1,038,964 underlying)
Footnotes (4)
- [F1]The Series B Preferred Shares converted into Common Shares on a 1-for-1 basis immediately prior to the completion of the Issuer's initial public offering of Common Shares and had no expiration date.
- [F2]These shares are held by the Stein Family LLC, for which the Reporting Person serves as the managing member.
- [F3]The Series E Preferred Shares converted into Common Shares on a 1.2-for-1 basis immediately prior to the completion of the Issuer's initial public offering of Common Shares and had no expiration date.
- [F4]These shares are held by Lipoterx, Ltd. ("Lipoterx"). Lipoterx Holdings, LLC, the general partner of Lipoterx, has sole voting and investment power with respect to the shares held by Lipoterx. The Reporting Person, the managing partner of Lipoterx Holdings, LLC has sole voting and investment power with respect to the shares held by Lipoterx.
Documents
Issuer
Xenon Pharmaceuticals Inc.
CIK 0001582313
Entity typeoperating
IncorporatedBritish Columbia, Canada
Related Parties
1- filerCIK 0001582313
Filing Metadata
- Form type
- 4
- Filed
- Nov 11, 7:00 PM ET
- Accepted
- Nov 12, 8:33 PM ET
- Size
- 12.1 KB